S. Srinivas

Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate

Melinda L. Telli, Ronald Witteles, George A. Fisher et al. · Annals of Oncology · 2008 · 237 citations · Full text

Oncology, Medicine, Anti-cancer Agent +3

Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials

D.Y.C. Heng, Toni K. Choueiri, Brian I. Rini et al. · Annals of Oncology · 2013 · 144 citations · Full text

Urology, Genitourinary Cancer, Eligibility Criteria +6

A phase II trial of intra-patient dose-escalated sorafenib in patients (pts) with metastatic renal cell cancer (MRCC)

R. J. Amato, Patricia Harris, Martin L. Dalton et al. · Journal of Clinical Oncology · 2007 · 85 citations

Therapeutic Drug Monitoring, Intra-patient Dose-escalated Sorafenib, Urology +15

Bevacizumab with or without erlotinib in metastatic renal cell carcinoma (RCC)

Ronald M. Bukowski, Fairooz F. Kabbinavar, Robert A. Figlin et al. · Journal of Clinical Oncology · 2006 · 83 citations

Surgical Oncology, Cancer Management, Immunology +16

Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC)

Aristotelis Bamias, Kimon Tzannis, L.C. Harshman et al. · Annals of Oncology · 2017 · 71 citations · Full text

Surgical Oncology, Urology, Urologic Cancer Epidemiology +9